Global Cancer Monoclonal Antibodies Market Report 2020-2030: Focus on Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix)
December 22, 2020 05:38 ET
|
Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. ...
7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
November 09, 2020 05:30 ET
|
7 Hills Pharma
HOUSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...
Global PD-1/PD-L1 Immunotherapy Market Analysis and Forecast, 2019-2020 & 2030
October 23, 2020 04:53 ET
|
Research and Markets
Dublin, Oct. 23, 2020 (GLOBE NEWSWIRE) -- The "Global PD-1/PD-L1 Immunotherapy Market: Focus on Type, Application, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast,...
Global Immuno-Oncology Market 2019-2020 & Forecast to 2024 with Impact Analysis of COVID-19
October 06, 2020 03:54 ET
|
Research and Markets
Dublin, Oct. 06, 2020 (GLOBE NEWSWIRE) -- The "Global Immuno-Oncology Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's...
Global Immuno-Oncology Diagnostics Markets 2020-2024: Focus on Biomarkers and the Next Five Years
October 01, 2020 07:29 ET
|
Research and Markets
Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "The Race for Biomarkers Market Forecasts for Immuno-Oncology Diagnostics, With Exutive and Consultant Guides and including Customized Forecasting and...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
September 18, 2020 03:05 ET
|
Autolus Therapeutics plc
- AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE...
Global Immuno-Oncology Diagnostics Market 2019-2023 - Outcome Potential, Companion Diagnostics, Funding, Technology Environment, and Target Solutions Driving Growth
August 27, 2020 06:48 ET
|
Research and Markets
Dublin, Aug. 27, 2020 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Diagnostics: The Race for Biomarkers - Market Forecasts for Immuno-Oncology Diagnostics - With Executive and Consultant Guides and...
Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia
April 16, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL
April 07, 2020 07:00 ET
|
Precision Biosciences
PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic FDA has authorized Precision to begin dosing with PBCAR20A at Dose Level 2 DURHAM,...
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate
December 09, 2019 07:00 ET
|
Precision Biosciences
-PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%)...